Corporate ActionJul 23, 2026, 09:10 PM
Scribe Therapeutics Prices Upsized IPO at $15.00/Share, Raising $128.7M
AI Summary
Scribe Therapeutics announced the pricing of its upsized initial public offering of 8,580,000 shares of common stock at $15.00 per share, the high end of the range. This offering is expected to generate gross proceeds of $128.7 million. The company also granted underwriters an option to purchase an additional 1,287,000 shares. Concurrently, Scribe Therapeutics agreed to sell 500,000 shares to Sanofi in a private placement at the same price.
Key Highlights
- Priced upsized initial public offering of 8,580,000 shares.
- IPO priced at $15.00 per share, high end of the range.
- Expected gross proceeds from IPO are $128.7 million.
- Underwriters have 30-day option to purchase additional 1,287,000 shares.
- Shares expected to begin trading on Nasdaq Global Market on July 24, 2026, under SCTX.
- Concurrent private placement of 500,000 shares to Sanofi at $15.00 per share.
Price Impact
More from SCTX